Hims & Hers Health Financials - Benzinga

Hims & Hers Health Inc

HIMSNYSE

Trade with Public

Trade with Public

$29.79

1.093.8%

가까이에: Sep 30, 5:00 PM EST

$29.85

0.060.2%

시간외: 5:26 PM EST

개요 뉴스 실적 전망 이벤트 목표가재무심리 지분 현황 비교 옵션 주식 보고서

Hims & Hers Health Financials

Hims & Hers Health (HIMS) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

Hims & Hers Health: Investments Necessary For Long-Term Incremental Growth, Says Bullish Analyst

HIMS stock edges lower after mixed Q2 results. Needham analyst maintains Buy rating, raises PT to $42. Company's revenue up 38.2% YoY.

Priya Nigam

Hims & Hers Shares Drop After Mixed Q2 Earnings — Details

Hims & Hers posted Q2 results - here are the details you need to know.

Erica Kollmann

PRO
Hims & Hers Health Sees Q3 Sales $880.000M-$900.000M vs $793.071M Est

Hims & Hers Health (NYSE:HIMS) sees Q3 sales of $880.000 million-$900.000 million vs $793.071 million analyst estimate.

Benzinga Newsdesk

PRO
Hims & Hers Health Raises FY2026 Sales Guidance from $2.800B-$3.000B to $3.100B-$3.300B vs $2.928B Est

Hims & Hers Health (NYSE:HIMS) raises FY2026 sales outlook from $2.800 billion-$3.000 billion to $3.100 billion-$3.300 billion vs $2.928 billion estimate.

Benzinga Newsdesk

PRO
Hims & Hers Health Q2 EPS $(0.37) Misses $(0.03) Estimate, Sales $753.214M Beat $699.889M Estimate

Hims & Hers Health (NYSE:HIMS) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.03) by 1133.33 percent. This is a 317.65 percent decrease over earnings of $0.17 per

Benzinga Newsdesk

Hims & Hers Health Likely To Report Q2 Loss; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

HIMS to release Q2 earnings on Aug. 10, expected to report a loss of 5 cents/share. FDA panel voted to add BPC-157 to compounding list. Stock rose 6.5% on Friday.

Avi Kapoor

© 2026 Benzinga | All Rights Reserved